Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Tran, Chris, Ouk, Samedy, Clegg, Nicola J., Chen, Yu, Watson, Philip A., Arora, Vivek, Wongvipat, John, Smith-Jones, Peter M. +11 more·2009·Science
DOI 10.1126/science.1168175

Cited by (1,000)

Items 101–200 of 1,000

  1. Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100
    Juliet Richards, Ai Chiin Lim, Colin W. Hay, ANGELA E. R. TAYLOR, Anna Wingate, Karolina Nowakowska, Carmel Jo Pezaro, Suzanne Carreira, JANE C. GOODALL, Wiebke Arlt et al. · 2012 · Cancer Research
  2. Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
    Raymond A. Pagliarini, Wenlin Shao, William R. Sellers · 2015 · EMBO Reports
  3. Peptidomimetic targeting of critical androgen receptor–coregulator interactions in prostate cancer
    Preethi Ravindranathan, Tae-Kyung Lee, Lin Yang, Margaret M. Centenera, Lisa M. Butler, Wayne D. Tilley, Jer‐Tsong Hsieh, Jung‐Mo Ahn, Ganesh V. Raj · 2013 · Nature Communications
  4. Capturing tumor complexity in vitro: Comparative analysis of 2D and 3D tumor models for drug discovery
    Stock, Kristin, Estrada, Marta F., Vidic, Suzana, Gjerde, Kjersti, Rudisch, Albin, Santo, Vítor E., Barbier, Michaël, Blom, Sami, Arundkar, Sharath C., Selvam, Irwin et al. · 2016 · Scientific Reports
  5. Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer
    Maria Thadani‐Mulero, Luigi Portella, Shihua Sun, Matthew S. Sung, Alexandre Matov, Robert L. Vessella, Eva Corey, David M. Nanus, Stephen R. Plymate, Paraskevi Giannakakou · 2014 · Cancer Research
  6. Breast and prostate cancer: more similar than different
    Gail Petuna Risbridger, Ian D. Davis, Stephen N. Birrell, Wayne D. Tilley · 2010 · Nature reviews. Cancer
  7. Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer
    Eleni Efstathiou, Mark Anton Titus, Sijin Wen, Anh G. Hoang, Μαρία Κάρλου, Robynne Ashe, Shi Ming Tu, Ana M. Aparicio, Patricia Troncoso, James Lloyd Mohler et al. · 2014 · European Urology
  8. Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?
    Attard, Gerhardt, Cooper, Colin S., de Bono, Johann S. · 2009 · Cancer Cell
  9. Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide In Vivo
    Valerie N. Barton, Nicholas C. D’Amato, Melita A. Gordon, Hanne Lind, Nicole S. Spoelstra, Beatrice L. Babbs, Richard E. Heinz, ANTHONY D. ELIAS, Paul Jedlicka, Britta M. Jacobsen et al. · 2015 · Molecular Cancer Therapeutics
  10. Analysis of the androgen receptor–regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression
    Yajia Zhang, Sethuramasundaram Pitchiaya, Marcin P. Cieslik, Yashar S. Niknafs, Jean Ching-Yi Tien, Yasuyuki Hosono, Matthew K. Iyer, Sahr Yazdani, Shruthi Subramaniam, Sudhanshu Kumar Shukla et al. · 2018 · Nature Genetics
  11. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer
    Giuseppe Galletti, Benjamin I. Leach, Linda Lam, Scott T. Tagawa · 2017 · Cancer Treatment Reviews
  12. Androgen Receptor Function and Androgen Receptor–Targeted Therapies in Breast Cancer
    Miho Kono, Takeo Fujii, Bora Lim, Meghan Sri Karuturi, Debu Tripathy, Naoto Tada Ueno · 2017 · JAMA Oncology
  13. The complexity of prostate cancer: genomic alterations and heterogeneity
    Lara K. Boyd, Xueying Mao, Yong‐Jie Lu · 2012 · Nature Reviews Urology
  14. Targeting the MLL complex in castration-resistant prostate cancer
    Rohit Malik, Amjad P. Khan, Irfan Ahmed Asangani, Marcin P. Cieslik, John R. Prensner, Xiaoju Wang, Matthew K. Iyer, Xia Jiang, Dmitry Borkin, June F Escara-Wilke et al. · 2015 · Nature Medicine
  15. Castration-Resistant Prostate Cancer: AUA Guideline Amendment
    Michael S. Cookson, William T. Lowrance, Mohammad Hassan Murad, Adam Stuart Kibel · 2014 · The Journal of Urology
  16. A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities
    Rong Hu, William B. Isaacs, Jun Luo · 2011 · The Prostate
  17. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial
    Karim S. Fizazi, Howard I. Scher, Kurt Miller, Ethan Basch, Cora Nanette Sternberg, David F Cella, David Forer, Mohammad Hirmand, Johann Sebastian De Bono · 2014 · The Lancet Oncology
  18. Small‐Molecule‐Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging
    Gustafson, Jeffrey L., Neklesa, Taavi K., Cox, Carly S., Roth, Anke G., Buckley, Dennis L., Tae, Hyun Seop, Sundberg, Thomas B., Stagg, D. Blake, Hines, John, McDonnell, Donald P. et al. · 2015 · Angewandte Chemie International Edition
  19. Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
    Andrew J. Armstrong, Elizabeth S. Garrett-Mayer, Ronald de Wit, Ian F. Tannock, Mario A. Eisenberger · 2009 · Clinical Cancer Research
  20. Treatment of Advanced Prostate Cancer—A Review of Current Therapies and Future Promise
    Semini Sumanasuriya, Johann Sebastian De Bono · 2017 · Cold Spring Harbor Perspectives in Medicine
  21. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer
    Robert J. van Soest, Martin E. van Royen, Ellen S. de Morrée, Jan Matthijs Moll, Wilma J. Teubel, Erik A.C. Wiemer, Ron H.J. Mathijssen, Ronald de Wit, Wytske M. van Weerden · 2013 · European Journal of Cancer
  22. Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer
    Neel Shah, Ping Wang, John Wongvipat, Wouter R. Karthaus, Wassim M. Abida, Joshua Armenia, Shira Rockowitz, Yotam Drier, B Bernstein, Henry W. Long et al. · 2017 · eLife
  23. Evolution of androgen receptor targeted therapy for advanced prostate cancer
    Yien Ning Sophia Wong, Roberta Ferraldeschi, Gerhardt Attard, Johann Sebastian De Bono · 2014 · Nature Reviews Clinical Oncology
  24. Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis
    Zeyad D. Nassar, Chui Yan Mah, Jonas Dehairs, Ingrid J.G. Burvenich, Swati Irani, Margaret M. Centenera, Madison Helm, Raj Kumar Shrestha, Max V. Moldovan, Anthony Simon Don et al. · 2020 · eLife
  25. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
    Karim S. Fizazi, Christophe Massard, Petri Bono, Robert Jones, Vesa V Kataja, Nicholas David James, Jorge Alberto Garcia, Andrew S. Protheroe, Teuvo L.J. Tammela, Tony Elliott et al. · 2014 · The Lancet Oncology
  26. Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
    Qin Fu Feng, Bin He · 2019 · Frontiers in Oncology
  27. Distinct Patterns of Dysregulated Expression of Enzymes Involved in Androgen Synthesis and Metabolism in Metastatic Prostate Cancer Tumors
    Nicholas Mitsiades, Clifford C. Sung, Nikolaus D. Schultz, Daniel Costin Danila, Bin He, Vijay Kumar Eedunuri, Martin Fleisher, Chris Sander, Charles L. Sawyers, Howard I. Scher · 2012 · Cancer Research
  28. Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy
    Bo Cao, Yanfeng Qi, Guanyi Zhang, Duo Xu, Yang Zhan, Xavier A. Alvarez, Zhiyong Guo, Xueqi Fu, Stephen R. Plymate, Oliver A. Sartor et al. · 2014 · Oncotarget
  29. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study
    Benjamin A. Teply, Hao Wang, Brandon S. Luber, Rana Sullivan, Irina Rifkind, Ashley B. Bruns, Avery N. Spitz, Morgan Decarli, Victoria J. Sinibaldi, Caroline F. Pratz et al. · 2017 · The Lancet Oncology
  30. Perturbation Biology: Inferring Signaling Networks in Cellular Systems
    Evan J. Molinelli, Anil Korkut, Weiqing Wang, Martin L. Miller, Nicholas Paul Gauthier, Xiaohong Jing, Poorvi Kaushik, Qin He, Gordon Brent Mills, David B. Solit et al. · 2013 · PLoS Computational Biology
  31. Anoikis and EMT: Lethal "Liaisons" during Cancer Progression
    Zheng Cao, Theodore Livas, Natasha Kyprianou · 2016 · Critical Reviews™ in Oncogenesis
  32. NF-κB2/p52 Induces Resistance to Enzalutamide in Prostate Cancer: Role of Androgen Receptor and Its Variants
    Nagalakshmi Nadiminty, Ramakumar Tummala, Chengfei Liu, Joy C. Yang, Wei Lou, Christopher P. Evans, Allen C. Gao · 2013 · Molecular Cancer Therapeutics
  33. Androgen receptor (AR) aberrations in castration-resistant prostate cancer
    Kati K. Waltering, Alfonso Urbanucci, Tapio Visakorpi · 2012 · Molecular and Cellular Endocrinology
  34. Molecular events in neuroendocrine prostate cancer development
    Yong Wang, Yu Wang, Xinpei Ci, Stephen Y. C. Choi, Francesco Crea, Dong Lin, Yuzhuo Z. Wang · 2021 · Nature Reviews Urology
  35. MicroRNA let-7c Suppresses Androgen Receptor Expression and Activity via Regulation of Myc Expression in Prostate Cancer Cells
    Nagalakshmi Nadiminty, Ramakumar Tummala, Wei Lou, Yezi Zhu, Jin Zhang, Xinbin Chen, Ralph Devere White, Hsing‐Jien Kung, Christopher P. Evans, Allen C. Gao · 2011 · Journal of Biological Chemistry
  36. New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway
    Gerhardt Attard, Juliet Richards, Johann Sebastian De Bono · 2011 · Clinical Cancer Research
  37. Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology
    Amit J. Sabnis, Trever Grant Bivona · 2019 · Trends in Molecular Medicine
  38. Androgen action and metabolism in prostate cancer
    Sean M. Green, Elahe A. Mostaghel, Peter S. Nelson · 2012 · Molecular and Cellular Endocrinology
  39. 2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer
    Arnaud Blomme, Catriona A. Ford, Ernest J. Mui, Rachana Patel, Chara Ntala, Lauren E. Jamieson, Mélanie Planque, Grace H. McGregor, Paul Peixoto, Éric Hervouet et al. · 2020 · Nature Communications
  40. Transcriptional mediators of treatment resistance in lethal prostate cancer
    Meng Xiao He, Michael S. Cuoco, Jett P. Crowdis, Alice Bosma-Moody, Zhenwei Zhang, Kevin Bi, Abhay Kanodia, Mei-Ju Su, Sheng‐Yu Ku, Maria Mica Garcia et al. · 2021 · Nature Medicine
  41. Potential inhibitory effect of lycopene on prostate cancer
    Mahdi Mirahmadi, Shayan Azimi-Hashemi, Ehsan Saburi, Hossein Kamali, Mandana Pishbin, Farzin Hadizadeh · 2020 · Biomedicine & Pharmacotherapy
  42. Targeting Continued Androgen Receptor Signaling in Prostate Cancer
    Christophe Massard, Karim S. Fizazi · 2011 · Clinical Cancer Research
  43. Broad-spectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activation
    Pencheva, Nora, Buss, Colin G., Posada, Jessica, Merghoub, Taha, Tavazoie, Sohail F. · 2014 · Cell
  44. Cabazitaxel
    Matthew D. Galsky, Argyris Dritselis, Peter N. Kirkpatrick, William K. Oh · 2010 · Nature Reviews Drug Discovery
  45. Sox2 Is an Androgen Receptor-Repressed Gene That Promotes Castration-Resistant Prostate Cancer
    Steven Kregel, Kyle J. Kiriluk, Alex M. Rosen, Yi Cai, Edwin E. Reyes, Kristen B. Otto, Westin R Tom, G. Paner, R. Szmulewitz, D. V. Vander Griend · 2013 · PLoS ONE
  46. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial
    Matthew Robert Sydes, Mahesh Parmar, Malcolm David Mason, Noel William Clarke, Claire L. Amos, John Anderson, Johann Sebastian De Bono, David Paul Dearnaley, John Dwyer, Charlene Green et al. · 2012 · Trials
  47. Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer
    Hanling Wang, Ni Li, Qiuli Liu, Jiacheng Guo, Qiang Pan‐Hammarström, Bisheng Cheng, Junyu Xu, Baijun Dong, Guanjie Yang, Bin Yang et al. · 2023 · Cancer Cell
  48. Targeting the Androgen Signaling Axis in Prostate Cancer
    Charles Sichao Dai, Scott M. Dehm, Nima Sharifi · 2023 · Journal of Clinical Oncology
  49. Targeting androgen receptor phase separation to overcome antiandrogen resistance
    Jingjing Xie, Hao He, Wenna Kong, Ziwen Li, Zhenting Gao, Daoqing Xie, Lin Sun, Xiaofei Fan, Xiangqing Jiang, Qiangang Zheng et al. · 2022 · Nature Chemical Biology
  50. Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer
    Han, Xin, Zhao, Lijie, Xiang, Weiguo, Qin, Chong, Miao, Bukeyan, McEachern, Donna, Wang, Yu, Metwally, Hoda, Wang, Lu, Matvekas, Aleksas et al. · 2021 · Journal of Medicinal Chemistry
  51. TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer
    Michael D. Nyquist, Yingming Li, Tae Hyun Hwang, Luke S. Manlove, Robert L. Vessella, Kevin A.T. Silverstein, Daniel F. Voytas, Scott M. Dehm · 2013 · Proceedings of the National Academy of Sciences
  52. Converting Cancer Therapies into Cures: Lessons from Infectious Diseases
    Michael S. Glickman, Charles L. Sawyers · 2012 · Cell
  53. Non-canonical functions of the RB protein in cancer
    Frederick A. Dick, David W. Goodrich, Julien Sage, Nicholas J. Dyson · 2018 · Nature reviews. Cancer
  54. ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer
    Laura Cato, Jonas de Tribolet-Hardy, Irene I. Lee, Jaice T. Rottenberg, Ilsa M. Coleman, Diana Melchers, René Houtman, Tengfei Xiao, Wěi Li, Takuma Uo et al. · 2019 · Cancer Cell
  55. An update on androgen deprivation therapy for prostate cancer
    Nima Sharifi, James L. Gulley, William L. Dahut · 2010 · Endocrine Related Cancer
  56. Structural and functional biology of aldo-keto reductase steroid transforming enzymes
    Penning, Trevor M, Wangtrakuldee, Phumvadee, Auchus, Richard J · 2019 · Endocrine Reviews
  57. New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety
    Himisha Beltran, Tomasz M. Beer, Michael Anthony Carducci, Johann Sebastian De Bono, Martin Edwin Gleave, Maha Hussain, William Kevin Kelly, Fred Saad C, Cora Nanette Sternberg, Scott T. Tagawa et al. · 2011 · European Urology
  58. Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation
    Zeda Zhang, Chuanli Zhou, Xiaoling Li, Spencer D. Barnes, Su Deng, Elizabeth Hoover, Chi-Chao Chen, Young Sun Lee, Yanxiao Zhang, Choushi Wang et al. · 2020 · Cancer Cell
  59. BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer
    Irfan Ahmed Asangani, Kari Wilder-Romans, Vijaya L. Dommeti, Pranathi Meda Krishnamurthy, Ingrid J. Apel, June F Escara-Wilke, Stephen R. Plymate, Nora Maria Navone, Shaomeng Wang, Felix Yi-Chung Feng et al. · 2016 · Molecular Cancer Research
  60. Photodynamic Therapy for Metastatic Melanoma Treatment: A Review
    Channay Naidoo, Cherie Ann Kruger, Heidi Abrahamse · 2018 · Technology in Cancer Research & Treatment
  61. Pharmacokinetic Drug Interaction Studies with Enzalutamide
    Jacqueline A. Gibbons, Michiel de Vries, Walter J. J. Krauwinkel, Yoshiaki Ohtsu, Jan Noukens, Jan‐Stefan van der Walt, Roelof Mol, Joyce J. Mordenti, Taoufik Ouatas · 2015 · Clinical Pharmacokinetics
  62. Nuclear receptors: recent drug discovery for cancer therapies.
    Lin-Jie Zhao, Sheng-Tao Zhou, J. Gustafsson · 2019 · Endocrine reviews
  63. Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance
    Su Deng, Choushi Wang, Yunguan Wang, Yaru Xu, Xiaoling Li, Nickolas A. Johnson, Atreyi Mukherji, U‐Ging Lo, Lingfan Xu, Julisa Gonzalez et al. · 2022 · Nature Cancer
  64. Cooperative Dynamics of AR and ER Activity in Breast Cancer
    Nicholas C. D’Amato, Melita A. Gordon, Beatrice L. Babbs, Nicole S. Spoelstra, Kiel Butterfield, Kathleen C. Torkko, Vernon T. Phan, Valerie N. Barton, Thomas J. Rogers, Carol A. Sartorius et al. · 2016 · Molecular Cancer Research
  65. Clinical Pharmacokinetic Studies of Enzalutamide
    Jacqueline A. Gibbons, Taoufik Ouatas, Walter J. J. Krauwinkel, Yoshiaki Ohtsu, Jan‐Stefan van der Walt, Vanessa C. Beddo, Michiel de Vries, Joyce J. Mordenti · 2015 · Clinical Pharmacokinetics
  66. Androgen Receptor in Breast Cancer—Clinical and Preclinical Research Insights
    Aristomenis Anestis, Ilianna Zoi, Athanasios G. Papavassiliou, Michalis V. Karamouzis · 2020 · Molecules
  67. Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer
    Lamont, Kristin R., Tindall, Donald J. · 2011 · Molecular Endocrinology
  68. Androgen-induced Long Noncoding RNA (lncRNA) SOCS2-AS1 Promotes Cell Growth and Inhibits Apoptosis in Prostate Cancer Cells
    Aya Misawa, Ken‐ichi Takayama, Tomohiko Urano, Satoshi Inoue · 2016 · Journal of Biological Chemistry
  69. Natural-Products-Inspired Use of the gem -Dimethyl Group in Medicinal Chemistry
    Tanaji T. Talele · 2017 · Journal of Medicinal Chemistry
  70. Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer
    Kathryn E. Ware, Mariano A. García-Blanco, Andrew J. Armstrong, Scott M. Dehm · 2014 · Endocrine Related Cancer
  71. Second generation androgen receptor antagonists and challenges in prostate cancer treatment
    Yanhua Chen, Qianqian Zhou, William Hankey, Xiaosheng Fang, Fuwen Yuan · 2022 · Cell Death and Disease
  72. Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer
    Jack A. Schalken, John M. Fitzpatrick · 2015 · British Journal of Urology
  73. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens
    E. David Crawford, Paul F. Schellhammer, David G. McLeod, Judd W. Moul, Celestia S. Higano, Neal D. Shore, Louis Denis, Peter Iversen, Mario A. Eisenberger, Fernand Labrie · 2018 · The Journal of Urology
  74. Androgen Receptor on the Move: Boarding the Microtubule Expressway to the Nucleus
    Maria Thadani‐Mulero, David M. Nanus, Paraskevi Giannakakou · 2012 · Cancer Research
  75. Overcoming docetaxel resistance in prostate cancer: a perspective review
    Clara Hwang · 2012 · Therapeutic Advances in Medical Oncology
  76. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance
    Joshi J. Alumkal, Duanchen Sun, Eric Lu, Tomasz M. Beer, GEORGE V. THOMAS, Emile J. Latour, Rahul Raj Aggarwal, Jeremy Paul Cetnar, Charles J. Ryan, Shaadi Tabatabaei et al. · 2020 · Proceedings of the National Academy of Sciences
  77. The changing therapeutic landscape of castration-resistant prostate cancer
    Timothy Anthony Yap, Andrea Zivi, Aurelius Gabriel Omlin, Johann Sebastian De Bono · 2011 · Nature Reviews Clinical Oncology
  78. Molecular States Underlying Androgen Receptor Activation: A Framework for Therapeutics Targeting Androgen Signaling in Prostate Cancer
    Peter S. Nelson · 2011 · Journal of Clinical Oncology
  79. AKR1C3 as a target in castrate resistant prostate cancer
    Adeniji, Adegoke O., Chen, Mo, Penning, Trevor M. · 2013 · The Journal of Steroid Biochemistry and Molecular Biology
  80. Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer
    Alfonso Urbanucci, Biswajyoti Sahu, Janne Seppälä, Antti Larjo, Leena Latonen, Kati K. Waltering, Teuvo L.J. Tammela, R L Vessella, Harri J Lähdesmäki, Olli A. Jänne et al. · 2011 · Oncogene
  81. Development and prevalence of castration-resistant prostate cancer subtypes
    Jordan E. Vellky, William A. Ricke · 2020 · Neoplasia
  82. Resistance to second-generation androgen receptor antagonists in prostate cancer
    Keith Thomas Schmidt, Alwin D. R. Huitema, Cindy H. Chau, William Douglas Figg · 2021 · Nature Reviews Urology
  83. Determinants of Receptor- and Tissue-Specific Actions in Androgen Signaling
    Päivi Pihlajamaa, Biswajyoti Sahu, Olli A. Jänne · 2015 · Endocrine Reviews
  84. Drug discovery in advanced prostate cancer: translating biology into therapy
    Timothy Anthony Yap, Alan David Smith, Roberta Ferraldeschi, Bissan Al‐Lazikani, Paul Workman, Johann Sebastian De Bono · 2016 · Nature Reviews Drug Discovery
  85. Androgen deprivation of prostate cancer: Leading to a therapeutic dead end
    A. Katzenwadel, Philipp Wolf · 2015 · Cancer Letters
  86. Androgen receptor antagonists for prostate cancer therapy
    Christine Helsen, Thomas Van den Broeck, Arnout R. D. Voet, Stefan Preković, Hendrik Van Poppel, Steven Joniau, Frank Claessens · 2014 · Endocrine Related Cancer
  87. Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance
    Daniel James Crona, Young E. Whang · 2017 · Cancers
  88. Adverse effects of androgen‐deprivation therapy in prostate cancer and their management
    Handoo Rhee, Jennifer H. Gunter, Peter S Heathcote, Ken K. Y. Ho, Phillip D. Stricker, Niall M. Corcoran, Colleen C. Nelson · 2014 · British Journal of Urology
  89. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatment
    Badrising, Sushil, van der Noort, Vincent, van Oort, Inge M., van den Berg, H. Pieter, Los, Maartje, Hamberg, Paul, Coenen, Jules L., van den Eertwegh, Alfons J. M., de Jong, Igle J., Kerver, Emile D. et al. · 2014 · Cancer
  90. Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer
    Yu Zhao, Liguo Wang, Shancheng Ren, Lan Wang, Patrick R. Blackburn, Melissa S. McNulty, Xu Gao, Meng Qiao, Robert L. Vessella, Manish Kohli et al. · 2016 · Cell Reports
  91. Neoadjuvant Enzalutamide Prior to Prostatectomy
    Bruce Montgomery, Maria Tretiakova, Anthony Michael Joshua, Martin Edwin Gleave, Neil Eric Fleshner, Glenn J. Bubley, Elahe A. Mostaghel, Kim N. Chi, Daniel Wei Lin, Martin George Sanda et al. · 2016 · Clinical Cancer Research
  92. ACK1/TNK2 Regulates Histone H4 Tyr88-phosphorylation and AR Gene Expression in Castration-Resistant Prostate Cancer
    Kiran N. Mahajan, Pavani Malla, Harshani R. Lawrence, Zhihua Chen, Chandan Kumar‐Sinha, Rohit Malik, Sudhanshu Kumar Shukla, Jongphil Kim, Domenico Coppola, Nicholas J. Lawrence et al. · 2017 · Cancer Cell
  93. The treatment landscape of metastatic prostate cancer
    Yasutaka Yamada, Himisha Beltran · 2021 · Cancer Letters
  94. Adaptation or selection—mechanisms of castration-resistant prostate cancer
    Yang Zong, Andrew S. Goldstein · 2012 · Nature Reviews Urology
  95. Molecular Pathogenesis and Progression of Prostate Cancer
    Randy S. Schrecengost, Karen E. Knudsen · 2013 · Seminars in Oncology
  96. Selectively Targeting the DNA-binding Domain of the Androgen Receptor as a Prospective Therapy for Prostate Cancer
    Kush Dalal, Mani Roshan‐Moniri, Aishwariya Sharma, Huifang Li, Fuqiang Ban, Mohamed Hessein, Michael Hsing, Kriti Singh, Eric Leblanc, Scott M. Dehm et al. · 2014 · Journal of Biological Chemistry
  97. Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer
    Farshid Dayyani, Gary E. Gallick, Christopher J. Logothetis, Paul Gettys Corn · 2011 · JNCI Journal of the National Cancer Institute
  98. A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer
    Daniel Westaby, Maria D. Fenor de la Maza, Alec Paschalis, Juan M. Jiménez‐Vacas, Jon C. Welti, Johann Sebastian De Bono, Adam Sharp · 2021 · The Annual Review of Pharmacology and Toxicology
  99. Androgen Receptor Antagonists in Castration-Resistant Prostate Cancer
    Dana E. Rathkopf, Howard I. Scher · 2013 · The Cancer Journal
  100. Targeting the adaptive molecular landscape of castration‐resistant prostate cancer
    Alexander William Wyatt, Martin Edwin Gleave · 2015 · EMBO Molecular Medicine